Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration

Annals of Oncology

Volumn 17, Issue 9, 2006, Pages 1393-1398

  Semple, S I K ^a   Staff, R T ^b   Heys, S D ^a   Redpath, T W ^a   Welch, A E ^a   Ahearn, T S ^a   Hutcheon, A W ^c   Gilbert, F J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NHS GRAMPIAN   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; Chemotherapy; Delivery; Dynamic MRI; Efficacy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE;

ADULT; ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAGET NIPPLE DISEASE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 33748741191     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl136     Document Type: Article

References (29)

1. Minckwitz G von, Costa SD, Eirmann W et al. Maximised reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999; 7: 1999-2005.
2. Heys SD, Sarkar TK, Hutcheon AW et al. Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer. Expert Opin Pharmaco 2004; 5: 2147-2157.
3. Smith IC, Welch AE, Hutcheon AW et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 2000; 18: 1676-1688.
4. Semple SIK, Gilbert FJ, Redpath TW et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Euro Radiol 2004; 14: 2038-2045.
5. Fornage BD, Toubas O, Morel M. Clinical, mammographic and sonographic determination of pre-operative breast cancer. Cancer 1987; 60: 765-771.
6. Vinnicombe SJ, MacVicar AD, Guy RL et al. Primary breast cancer: mammographic changes after neo-adjuvant chemotherapy, with pathologic correlation. Radiology 1996; 198: 333-340.
7. Junkermann H, Founier D von. Imaging procedures for assessment of the response of mammary carcinoma to preoperative chemotherapy. Radiology 1997; 37: 726-732.
8. Semple SIK, Gilbert FJ, Redpath TW et al. Correlation of MRI-PET rim enhancement in breast cancer. A delivery related phenomenon with therapy implications? Lancet Oncol 2003; 4: 759.
9. Esserman L, Kaplan E, Partridge S et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Surg Oncol 2001; 8: 549-559.
10. Flickinger FW, Allison JD, Sherry RM et al. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. Magn Reson Imaging 1993; 11: 617-620.
11. Kuhl CK. MRI of breast tumors. Eur Radiol 2000; 10: 46-58.
12. Wasser K, Klein SK, Fink C et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Euro Radiol 2003; 13: 80-87.
13. 1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-232.
14. 18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Euro Radiol 2001; 11: 2058-2070.
15. Knopp MV, von Tengg-Kobligk H, Choyke PL. Functional magnetic resonante imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther 2003; 2: 419-426.
16. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR in Biomed 2002; 15: 154-163.
17. Martincich L, Montemurro F, De Rosa G et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast 2004; 83: 67-76.
18. Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol 2003; 76: S60-S80.
19. Bombardieri E, Crippa F, Maffioli L et al. Nuclear medicine techniques for the study of breast cancer. Eur J Nucl Med 1998; 24: 809-824.
20. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med 1998; 4: 290-302.
21. Wahl RL, Zasadny K, Helvie M et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 1993; 11: 2101-2111.
22. Bassa P, Kim E, Inoue T et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-flourodeoxyglucose in breast cancer. J Nucl Med 1996; 37: 931-938.
23. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005; 73: 61-64.
24. Semple SIK, Redpath TW, Ahearn TS et al. Effect of accurate T1 calculation on pharmacokinetic analysis of primary breast cancer. In Proceedings of the 11th Annual Meeting of ISMRM, Toronto, Canada 2003; 1259.
25. Matsubayashi R, Matsuo Y, Edakuni G et al. Breast masses with peripheral rim enhancement on dynamic contrast enhanced MR images: Correlation of MR findings with histologic features and expression of growth factors. Radiology 2000; 217: 841-848.
26. Hylton N. Magnetic resonance imaging of the breast: Opportunities to improve breast cancer management. J Clin Oncol 2005; 23: 1678-1684.
27. Manton DJ, Chaturvedi A, Hubbard A et al. Neoadjuvant chemotherapy in breast cancer: Early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 2006; 94: 427-435.
28. Mankoff DA, Dunnwald LK, Gralow JR et al. Blood flow and metabolism in locally advanced breast cancer: Relationship to response to therapy. J Nucl Med 2002; 43: 500-509.
29. Heinisch M, Gallowitsch HJ, Mikosch P. Comparison of FDG-PET and dynamic contrast-enhanced MRI in the evaluation of suggestive breast lesions. Breast 2003; 12: 17-22.